Last updated: August 15, 2026

Application No. 18/260,654

BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF

Non-Final OA

Filed

Jul 07, 2023

Priority

Jan 08, 2021 — CN PCT/CN2021/070897 +1 more

Examiner

ISMAIL, REHANA

Art Unit

1625

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

BEIGENE, LTD.

OA Round

1 (Non-Final)

Interview Optional

— +32.8% interview lift. Examiner has a relatively high allowance rate (77%); +32.8% interview lift. A written response may suffice.

Based on 88 resolved cases, 2023–2026

Examiner Intelligence

ISMAIL, REHANA View full profile →

Grants 77% — above average

Career Allowance Rate

68 granted / 88 resolved

+17.3% vs TC avg

Strong +33% interview lift

Without

With

+32.8%

Interview Lift

resolved cases with interview

Typical timeline

3y 5m

Avg Prosecution

35 currently pending

Career history

123

Total Applications

across all art units

Statute-Specific Performance

§101

5.1%

-34.9% vs TC avg

§103

28.7%

-11.3% vs TC avg

§102

22.1%

-17.9% vs TC avg

§112

26.9%

-13.1% vs TC avg

Black line = Tech Center average estimate • Based on career data from 88 resolved cases

Prosecution Timeline

Jul 07, 2023

Application Filed

May 11, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/027,300

Patent 12686692

KRAS G12D INHIBITORS

3y 4m to grant Granted Jul 21, 2026

17/439,575

Patent 12673044

METHODS OF TREATING BORDERLINE PERSONALITY DISORDER

4y 9m to grant Granted Jul 07, 2026

17/781,507

Patent 12673918

SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES

4y 1m to grant Granted Jul 07, 2026

18/145,601

Patent 12673935

PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF

3y 6m to grant Granted Jul 07, 2026

17/603,273

Patent 12668584

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS FOR THERAPEUTIC USES

4y 8m to grant Granted Jun 30, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

77%

Grant Probability

99%

With Interview (+32.8%)

3y 5m (~4m remaining)

Median Time to Grant

Low

PTA Risk

Based on 88 resolved cases by this examiner. Grant probability derived from career allowance rate.